Dirk Witters
Directeur/Membre du Conseil chez IMMUNOPRECISE ANTIBODIES LTD.
Fortune : 2 328 $ au 30/04/2024
Profil
Dirk Witters has held director positions at ImmunoPrecise Antibodies Ltd.
and BioStrand BV.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 19/01/2024 | 1 950 ( 0,01% ) | 2 328 $ | 30/04/2024 |
Postes actifs de Dirk Witters
| Sociétés | Poste | Début |
|---|---|---|
| IMMUNOPRECISE ANTIBODIES LTD. | Directeur/Membre du Conseil | 05/09/2023 |
BioStrand BV
 BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The private company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMUNOPRECISE ANTIBODIES LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
BioStrand BV
BioStrand BV Miscellaneous Commercial ServicesCommercial Services Part of ImmunoPrecise Antibodies Ltd., BioStrand BV is a Belgian company that offers an AI-powered biotherapeutic SaaS platform to accelerate drug discovery. The private company is based in Diepenbeek, Belgium. BioStrand's LensAI provides data solutions for simplified management, insights, integration, and collaboration. The platform helps researchers discover drug discovery insights faster and master big omics data challenges with multi-dimensional integration. The company was founded in 2019 by Dirk Van Hyfte and Ingrid Brands, with Ingrid Brands serving as the CEO since then. BioStrand was acquired by ImmunoPrecise Netherlands BV on April 14, 2022 for $35.10 million. | Commercial Services |
